A Phase 2 Study of Neratinib with or without Fulvestrant in HER2-Positive ER-Positive Metastatic Breast Cancer
The purpose of this research study is to determine how well neratinib, by itself or together with Fulvestrant, works in treating breast cancer that has spread to other parts of the body. We will also be looking at the side effects associated with this combination of drugs.
This is a Phase II study to determine how well neratinib, alone or together with Fulvestrant (FDA approved), works in treating breast cancer that has spread to other parts of the body.
Participants will not be paid for their participation.
- IRB Number: 1803730353 (17-318)
- Research Study Identifier: TX8968
- Principal Investigator: Tarah Ballinger, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required